MB-110 (Mustang Bio)

N/A

Report date: 2023/10/26 16:58:54

Base Information

Drug NameMB-110 (Mustang Bio)

Drug Alias NameMB-110

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Leukocyte-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector +[5]

Mechanisms of ActionV(D)J recombination-activating protein 1 gene transference

TargetsV(D)J recombination-activating protein 1

Therapy Area/IndicationsSevere Combined Immunodeficiency

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMustang Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio Inc

Inactive CompaniesN/A

Active IndicationsSevere Combined Immunodeficiency

Inactive IndicationsN/A

Other Information

ATC CodeN/A